Thirumalai SS, Shubin RA
Huntington Hospital Sleep Disorders Center, 100 West California Boulevard, CA 91107, Pasadena, USA
Sleep Med. 2000 Oct 1;1(4):313-316. doi: 10.1016/s1389-9457(00)00026-5.
Background: Cataplexy is a disabling component of the narcolepsy tetrad that is sometimes resistant to standard treatment.Case reports: Three of our patients with narcolepsy, including one who had post-traumatic narcolepsy, suffered from intractable cataplexy with failure of treatment with established drugs due to unacceptable side-effects.Results: We explored the use of citalopram (Celexa), the newest and most specific of the serotonin reuptake inhibitors, and were successful in treating cataplexy without significant side-effects. Stimulant drugs remained necessary for controlling symptoms of excessive drowsiness.Conclusions: Citalopram was effective in relieving the symptoms of resistant cataplexy in out patients.
猝倒是发作性睡病四联症的致残性组成部分，有时对标准治疗有抵抗性。
我们的三名发作性睡病患者，包括一名创伤后发作性睡病患者，患有难治性猝倒，因无法接受的副作用，使用既定药物治疗失败。
我们探索使用西酞普兰（喜普妙），这是最新且最具特异性的5-羟色胺再摄取抑制剂，成功治疗了猝倒且无明显副作用。仍需要使用兴奋剂药物来控制过度嗜睡症状。
西酞普兰有效缓解了我们患者中难治性猝倒的症状。
